FoRx Therapeutics’ Post

The American Association for Cancer Research annual meeting 5-10 April in San Diego is a big event for Tessellate BIO! Our senior leadership team and key R&D team members are attending to learn, network and share updates on how we are creating the next generation Synthetic Lethality precision oncology company.   We are redefining Synthetic Lethality in cancer beyond homologous recombination deficiency, turning cancer patients into cancer survivors. Our approach is to identify novel targets and treat cancers in a selective manner, using a combination of proprietary targets and dedicated diagnostic assays. We are building a first in class pipeline by exploiting synthetic lethal targets in DNA damage response (#DDR) pathways and loss-of-function (#LoF) of tumor suppressors. Our lead program targets Alternative Lengthening of Telomeres (#ALT) through the FANCM protein complex.   Catch one of us at #AACR24: Andree Blaukat (CEO), Katie Chapman (Head of Discovery Biology), Jürgen Moll, PhD (CSO), Laurent Rigoreau (Head of Medicinal Chemistry), Jana Wolf (Discovery Leader), Donata Federici Canova (Discovery Leader), and Joris Schuurmans (Head of Diagnostics).   Email: info@tessellatebio.com   Visit our website: www.tessellatebio.com for further information.   #PrecisonOncology #SyntheticLethality #DrugDiscovery 

🌟 Exciting Breakthrough in Cancer Research! 🌟 We are thrilled to share groundbreaking advancements from the research teams at Simon Fraser University, led by professors David Vocadlo and Rob Britton. This innovative technology significantly enhances therapeutic antibodies, making them far more potent in targeting various types of cancer. 🧬 Sugar-Blocking Technology: A Game Changer “𝘛𝘩𝘦 𝘪𝘮𝘱𝘳𝘰𝘷𝘦𝘥 𝘢𝘯𝘵𝘪𝘣𝘰𝘥𝘪𝘦𝘴 𝘤𝘢𝘯 𝘣𝘪𝘯𝘥 𝘶𝘱 𝘵𝘰 50-𝘧𝘰𝘭𝘥 𝘮𝘰𝘳𝘦 𝘱𝘰𝘵𝘦𝘯𝘵𝘭𝘺, 𝘮𝘢𝘬𝘪𝘯𝘨 𝘵𝘩𝘦𝘮 𝘧𝘢𝘳 𝘮𝘰𝘳𝘦 𝘦𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦, 𝘢𝘯𝘥 𝘵𝘩𝘪𝘴 𝘤𝘢𝘯 𝘢𝘭𝘴𝘰 𝘢𝘭𝘭𝘰𝘸 𝘺𝘰𝘶 𝘵𝘰 𝘵𝘢𝘳𝘨𝘦𝘵 𝘤𝘢𝘯𝘤𝘦𝘳𝘴 𝘵𝘩𝘢𝘵 𝘺𝘰𝘶 𝘸𝘰𝘶𝘭𝘥𝘯’𝘵 𝘯𝘰𝘳𝘮𝘢𝘭𝘭𝘺 𝘣𝘦 𝘢𝘣𝘭𝘦 𝘵𝘰 𝘢𝘵𝘵𝘢𝘤𝘬 𝘶𝘴𝘪𝘯𝘨 𝘢 𝘴𝘵𝘢𝘯𝘥𝘢𝘳𝘥 𝘢𝘯𝘵𝘪-𝘤𝘢𝘯𝘤𝘦𝘳 𝘢𝘯𝘵𝘪𝘣𝘰𝘥𝘺,” explains professor Vocadlo. At Technology Licensing Office (TLO) @ SFU, we are proud to support these innovative solutions being developed and commercialized by the SFU spin-off Carbaform Biosciences, addressing pressing health challenges. This breakthrough represents a significant step forward in the fight against cancer, underscoring the power of collaboration and innovation. Read more on GlycoNet: https://lnkd.in/dwBJyhdb

Mestastop® Solutions will be at Rotterdam Ahoy, Netherlands this June! Our Director, Debabani Roy Chowdhury, will present at #EACR2024 (Annual Congress of the European Association for Cancer Research). On June 12, 2024, she will discuss about "Identification and positioning of an approved drug, MS-AP-031*, to delay metastasis of primary colorectal cancer patients in adjuvant settings". About the EACR Congress "The 2024 Annual Congress of the European Association for Cancer Research (EACR 2024) is a four-day congress (10-13 June 2024) dedicated to basic, preclinical and translational cancer research across a wide breadth of topics. It will highlight the latest research and bring together the cancer research community to inspire innovation and build knowledge, connections and collaborations." - www.2024.eacr.org #cancer #oncology #metastasis #clinicaltrial #patentedtechnology #patent #netherlands #rotterdam #colorectalcancer #translationalresearch

In an recent interview with SelectScience®, study author Karina Eterovic, MSc, PhD, NYS CoQ, R&D Director of Oncology Diagnostics at Eurofins Viracor BioPharma Services, discussed the complex interplay between clonal hematopoiesis (CH) and cancer genomics, in the context of precision of oncology therapy development, cancer diagnosis and treatment. She shared the results of a recent study that emphasize the potential need to integrate routine germline sequencing into clinical practice to prevent the misclassification of CH aberrations. Findings identified somatic CH mutations in a substantial subset of patients with advanced solid tumors. This has implications for accurate treatment decisions in cancer patients, as distinguishing between tumor-derived mutations and CH mutations is crucial. Read more here: https://lnkd.in/ezM6KXWx #onocologyresearch #cancer #genomics #eurofins #testingforlife #biopharma Eurofins Bioanalytical Services Eurofins Central Laboratory Eurofins Clinical Trial Supplies

We will present preclinical proof-of-concept data for our proprietary lead programs, TUB-030 and TUB-040, targeting #SolidTumors at the upcoming American Association for Cancer Research’s Annual Meeting #AACR24. Our CSO, Jonas Helma-Smets, our CDO, Bjoern Hock, and our VP Biology & Translational Research, Annette Vogl, will be in San Diego, highlighting the preclinical differentiation of our ADC candidates in two poster presentations on April 8, 2024. Both candidates are characterized by disease-tailored composition and high stability, enabling an exceptionally wide therapeutic window. TUB-030 is directed against the #cancer antigen 5T4, expressed in a wide range of solid tumor indications. TUB-040 targets Napi2b, a well-characterized target in ovarian and lung cancer. Both candidates contain a topoisomerase-I-inhibitor as payload and are optimized for long-lasting, durable tumor engagement and minimal off-target toxicity. Find more details about the agenda and abstracts in the press release here: https://bit.ly/3SZ5Nq6 Stay tuned to learn more about the full preclinical data, which we will announce in a press release following the presentation at AACR.

A paper featuring CCR staff is mentioned in this post below. If you haven't yet, give the NCI Division of Cancer Treatment and Diagnosis a follow! 👇

Are you heading to the American Association for Cancer Research Conference (AACR) in San Diego? On Monday April 8, at 1:30pm, join Dewpoint's Head of Biology Ann Boija, Ph.D., who will be presenting the latest data from our colorectal cancer program (Poster section 53 - Poster Board 15 – Abstract LB199). These new data demonstrate how we were able to leverage condensate biology to discover small molecule condensate-modulators (c-mods) that reverse the hyperactive function of beta-catenin by entrapping it into depot condensates across models of genetically diverse colorectal cancers and several Wnt-associated cancers. These results highlight the promise of condensate biology in drugging previously intractable oncology targets and for developing novel treatments for patients suffering from diseases with high unmet need. Read about Ann’s ambitions for biomolecular condensates in oncology: https://lnkd.in/e5vuzDJs #AACR24

Hello, this is Dr. James Doroshow, DCTD Director. I wanted to let the scientific community know about how NCI’s research resources can uniquely enable cancer researchers to make crucial scientific advances. Here’s one collaborative example that was brought forth with help from researchers across institutions and divisions, including from within NCI Center for Cancer Research.   A first-in-class lactate dehydrogenase inhibitor developed through the NCI Experimental Therapeutics (NExT) Program/Chemical Biology Consortium showed cancer cell death and reduced tumor growth in a Hurthle cell carcinoma (HTC) PDX model that was sourced from the National Cancer Institute (NCI) Patient-Derived Models Repository (PDMR).   This work highlights the value of NCI’s research resources to advancements in this area of research, especially in a rare cancer: understanding the effectiveness of targeting glycolysis in tumor harboring mitochondria electron transfer complex mutations.   Learn more about the PDMR - https://pdmr.cancer.gov/ and the NExT Program - https://next.cancer.gov/ - and see a full list of DCTD research resources - https://lnkd.in/dkCpBTn7   Reference: https://lnkd.in/d48DuA-s

Excited to share that TD2 will be presenting three groundbreaking posters at the upcoming AACR meeting in April! 🌟 Join us to learn more about the latest advancements at TD2: https://hubs.li/Q02q8hnz0 Innovations in Glioblastoma Research - Discover our strides in utilizing PDX models integrated with patient history and whole exome sequencing to enhance preclinical studies. Combating KRAS/LKB1 Mutant Lung Cancer - Learn about our breakthroughs in epigenetic-based combination therapy showing promise against this challenging condition. Advancing Cell Cycle Inhibitor Studies - Explore our insights from the flow cytometry evaluation of cell cycle arrest in NSCLC cells following treatment with novel inhibitors. These studies underscore our commitment to advancing cancer research through innovative and translational approaches. For detailed insights into our findings and to connect with our team, visit https://hubs.li/Q02q8hnz0. Don't miss this opportunity to engage with us and learn more about our work in transforming cancer treatment. #AACR2024 #OncologyResearch #CancerResearch

📰 I am happy to share my first publication in regards to my PhD project. Titled "Design, optimization, characterization, and in vitro evaluation of metformin-loaded liposomes for triple negative breast cancer treatment" was recently published in Journal of Liposome research together with my thesis supervisors Emilie Allard-Vannier and katel herve aubert, as well as Rustem Uzbekov and Igor Chourpa. 🔎 Our projects focuses on repurposing antidiabetic drug metformin as an adjuvant in breast cancer therapy. In this work, specifically, we focused on vectorizing metformin inside liposomal drug delivery systems to overcome some pharmacokinetic challenges of administering metformin for cancer therapy. 💶This work was supported by the French National Research Agency under the program ‘Investissements d’avenir’ Grant Agreement LabEx MAbImprove (ANR-10-LABX-53–01) in particular Key Question 3 group and ‘PASHA’ project. 📌 The article can be found online: https://lnkd.in/exyC_xcx 🆓 50 free online copies can be found: https://lnkd.in/eTS6ZKj6